

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Drug treatments for COVID-19, endemic paediatric viral illnesses after COVID-19 disruption, duration of shedding of culturable Omicron

Peer reviewed journals featured:

- Systematic reviews on:
 - Drug treatments for COVID-19 (updated) [here](#)
 - Myocarditis & pericarditis after COVID-19 vaccination [here](#) and associated editorial [here](#)
 - The prevalence of psychological stress in student populations during COVID-19 [here](#)
- A narrative review on the origin, features and intervention of Omicron sublineages [here](#)
- Observational studies on:
 - Comirnaty (Pfizer) vaccine effectiveness against Omicron in 5 to 11 years of age [here](#)
 - Safety of heterologous vaccination with Vaxzevria (AstraZeneca) & mRNA vaccines [here](#)
 - Immune responses to mRNA vaccinations in patients with multiple sclerosis [here](#)
 - Effectiveness of a fourth dose of mRNA vaccine against all-cause mortality in long-term care facility residents and in the 'oldest old' [here](#)
 - High-density lipoprotein-cholesterol levels and susceptibility to COVID-19 [here](#)
 - Effectiveness of 2, 3, and 4 mRNA vaccine doses in immunocompetent adults [here](#)
 - Long-term immune response to SARS-CoV-2 infection after mild infection [here](#)
 - Reactogenicity of simultaneous mRNA booster and influenza vaccination [here](#) and associated commentary [here](#)
 - Immune responses in Omicron breakthrough infection in vaccinated adults [here](#)
 - Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater [here](#)
 - Impact of mild COVID-19 on balance function in young adults [here](#)
 - COVID-19 and the risk of atrial fibrillation in inpatients [here](#)
 - COVID-19 and risk of neurodegenerative disorders [here](#)
 - Effect of statins on COVID-19 risk, severity and fatal outcome [here](#)
 - The sequences of 150,119 genomes in the UK Biobank [here](#)
 - Safety of first mRNA vaccine booster doses in immunocompromised persons [here](#)
 - Comparative effectiveness of Vaxzevria (AstraZeneca) vs Comirnaty (Pfizer) vaccines in health and social care workers in England [here](#)
 - Comirnaty (Pfizer) & Vaxzevria (AstraZeneca) vaccines following second dose [here](#)
 - Burden of SARS-CoV-2 infection in healthcare workers and impact of vaccines in England [here](#) and associated editorial [here](#)
- A case report of cutaneous manifestations of COVID-19 [here](#)

- An editorial stating the NHS is not living with COVID-19, it's dying from it [here](#)
- Commentary on:
 - Endemic paediatric viral illnesses after COVID-19 disruption [here](#)
 - COVID-19 and the Dunning-Kruger effect [here](#)
 - One year on from UK's "Freedom Day," what have we learnt? [here](#)
 - A 7-point plan to suppress COVID-19 infections and reduce disruptions in the UK [here](#)
 - How COVID-19 unmasked the autoinflammatory PFAPA syndrome [here](#)

Letters and correspondence discussed:

- Duration of shedding of culturable virus in Omicron (BA.1) infection [here](#)
- Efficacy of antibodies and antiviral drugs for Omicron BA.2.12.1, BA.4, and BA.5 subvariants [here](#)
- Omicron neutralisation from inactivated and ZF2001 vaccines [here](#)
- Protection associated with previous SARS-CoV-2 infection in Nicaragua [here](#)
- Neutralisation sensitivity of Omicron subvariants to therapeutic monoclonal antibodies [here](#) and [here](#)

Pre-peer review articles featured:

- Long COVID in cancer patients [here](#)
- SARS-CoV-2 infections during BA.1 wave and subsequent immunity in Gauteng, South Africa [here](#)
- Fc effector activity and neutralisation against Omicron BA.4 subvariant [here](#)
- Neutralisation sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies [here](#)

Guidance and reports

- The World Health Organization published:
 - Its weekly epidemiological report on COVID-19 [here](#)
 - Updated guideline on drugs for COVID-19 [here](#)
- The UK Health Security Agency released its SARS-CoV-2 therapeutics technical briefing 4 [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) released its weekly update [here](#)
- The Canadian National Collaborating Centre for Methods and Tools published a rapid review of COVID-19 testing requirements in healthcare and long-term care settings [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to Moderna COVID-19 vaccine (SPIKEVAX) [here](#) and SPIKEVAX (elasomeran) [here](#) for use in children from 6 months

News and blogs

- High prevalence and lack of hospital beds putting "intense pressure" on ambulances in UK [here](#)
- Antimicrobial resistance rose dangerously in US during pandemic [here](#)
- An NHS doctor's personal pandemic experience [here](#)
- The COVID-19 Recovery trial set to lose funding as proposal to examine flu drugs is rejected [here](#)
- Omicron BA.5 variant is now dominant in US as infections rise [here](#)
- The hunt for drugs for mild COVID-19 [here](#)
- One coronavirus infection ward off another [here](#)